Colic Clinical Trial
Official title:
Phase I Safety and Tolerance of Lactobacillus Reuteri in Adults
This study will evaluate the safety and tolerability of the probiotic Lactobacillus reuteri (LR) in healthy adult patients. Patients will be randomized to receive either LR or placebo orally each day for a total of 60 doses. The effects on fecal bacteria, circulating white blood cell receptors and inflammatory cytokine profiles will be measured.
Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment and maintenance of a well-functioning gastro-intestinal (GI) tract micro flora and prevention and treatment of mild diarrhea associated with GI-tract infections. The oil drops contain a dietary supplement of Lactobacillus reuteri DSM 17938. The patients will receive 5 drops (10^8 live organisms) by mouth daily for 60 days. Daily administration will include 5 drops (5x10^8) of L. reuteri or placebo daily for two months. During this time,circulating peripheral blood mononuclear cell (PBMC) toll-like receptor-2 and -4 levels will be measured, along with PBMC cytokine production levels in vitro. Fecal DGGE analysis(with sequencing of bacterial rDNA) will be completed identifying changes in fecal microbiota. Inflammation in the gut will also be assessed by fecal calprotectin assay (ELISA). The time on study treatment is 2 months, with 4 months observation, for a total of 6 months. There will be 7 required visits, during which, we will assess safety and immune system effects. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01849991 -
Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic
|
Phase 1 | |
| Completed |
NCT01279265 -
Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Colic
|
N/A | |
| Completed |
NCT00177086 -
Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi
|
Phase 3 | |
| Not yet recruiting |
NCT02577133 -
Prevention of Colic With the Probiotic Lactobacillus Reuteri
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01715220 -
Treatment of Suspected Cholelithiasis With Nitroglycerin
|
Phase 2 | |
| Completed |
NCT02865564 -
Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics
|
N/A | |
| Completed |
NCT01997593 -
Peritoneal Ropivacaine Infiltration on Postoperative Pain in Children Affected
|
Phase 2 | |
| Completed |
NCT01541046 -
Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic
|
Phase 2 | |
| Completed |
NCT00929292 -
Safety and Tolerance Study of Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic
|
Phase 3 | |
| Recruiting |
NCT05554991 -
Human Milk Oligosaccharide (HMO) Supplementation in Colic Management
|
N/A | |
| Recruiting |
NCT01067027 -
Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri
|
Phase 4 | |
| Recruiting |
NCT04983069 -
Neonatal Outcome of Children With Antenatal Colic Hyperechogenicity
|
||
| Recruiting |
NCT05685030 -
Probiotics Strains for Infant Colic
|
Phase 2 | |
| Withdrawn |
NCT05198700 -
The Effect of Probiotics on Symptoms of Infantile Colic
|
Phase 2 | |
| Terminated |
NCT02586558 -
Effect of a Prebiotic on Colic and Crying and Fussing Behaviour in Infants
|
N/A | |
| Completed |
NCT01532518 -
Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance
|
Phase 2 | |
| Completed |
NCT00796523 -
An Intervention to Decrease Infant Crying
|
N/A | |
| Completed |
NCT05052476 -
First Line Dose-efficacy Study of Bactecal® D Liquid for Infant Colic
|
N/A | |
| Completed |
NCT02242292 -
Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort
|
Phase 2 | |
| Terminated |
NCT00139646 -
Parecoxib in Renal Colic
|
Phase 3 |